(Q55463103)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

editorial

0 references

title

Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

main subject

angiogenesis inhibitor

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1

Enrico Franceschi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

657-660

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

31 January 2020

cites work

1 reference

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

Angiogenesis as a therapeutic target in malignant gliomas

21 January 2018

1 reference

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

New agents and new end points for recurrent gliomas.

21 January 2018

1 reference

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

21 January 2018

1 reference

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21554036%20AND%20SRC:MED&resulttype=core&format=json

release_ynm4aoeqrzezfn2x6yxmck6qxe

31 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ynm4aoeqrzezfn2x6yxmck6qxe

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference